MMP inhibition in prostate cancer

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 271-289

  Lokeshwar, Bal L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; DOXYCYCLINE; MATRIX METALLOPROTEINASE; PACLITAXEL; TETRACYCLINE DERIVATIVE;

BONE METASTASIS; CONFERENCE PAPER; ENZYME INHIBITION; LUNG METASTASIS; NONHUMAN; PROSTATE CANCER; RAT; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0032864675     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07690.x     Document Type: Conference Paper

References (71)

1. 1. Landis, S.H., T. Murray, S. Bolden & P.A. Wingo. 1998. Cancer statistics, 1998. CA, Cancer J. Clin. 48(1): 6-29.
2. 2. Kirby, K.S. 1996. Recent advances in the medical management of prostate cancer. Br. J. Clin. Pract. 50: 88-93.
3. 3. Ismail, M. & L.G. Gomella. 1997. Current treatment of advanced prostate cancer. Tech Urol. 3(1): 16-24.
4. 4. Gites, R.F. 1991. Carcinoma of the prostate. N. Eng. J. Med. 324: 236-245.
5. 5. Droller, M.J. 1997. Medical approaches in the management of prostatic disease. Br. J. Urol. 79(Suppl 2): 42-52.
6. 6. Kirby, R.S., T.J. Christmas & M.K. Brawer. 1996. Prostate Cancer. Mosby, London.
7. 7. Schroder, F.H. 1993. Endocrine therapy for prostate cancer. Br. J. Urol. 71: 633-640.
8. 8. Cunha G.R., A.A. Donjacour, P.S. Cooke et al. 1987. The endocrinology and developmental biology of the prostate. Endocr. Rev. 8: 338-362.
9. 9. Aquilina J.W., J.I. Lipsky & D.G. Bostwick, 1997. Androgen deprivation as a strategy for prostate cancer chemoprevention. J. Natl. Cancer Inst. 89: 689-96.
10. 10. Newling, D.W. 1996. The management of hormone refractory prostate cancer. Eur. Urol. 29(Suppl. 2): 69-74.
11. 11. Raghavan, D., B. Koczwara & M. Javle, 1997. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur. J. Cancer 33(4): 566-574.
12. 12. Logothetis, C.J. 1993. Management of androgen-independent prostate carcinoma. In Prostate Diseases. H. Lepor & R.K. Lawson, Eds. W.B. Saunders. Philadelphia.
13. 13. Liotta, L.A. & W.G. Stettler-Stevenson. 1993. Principles of molecular cell biology of cancer: cancer metastasis. In Cancer: Principles and Practice of Oncology, 4th ed., V.T. De Vita, S. Hellman & S.A. Rosenberg, Eds.: 134-149. Lippincott. Philadelphia.
14. 14. Fidler, I.J. 1989. Origin and biology of cancer metastasis. Cytometry 10: 673-680.
15. 15. Chambers A.F., I.C. MacDonald, E.E. Schmidt et al. 1995. Steps in tumor metastasis: new concepts from intra vital video-microscopy. Cancer Met. Rev. 14: 279-301.
16. 16. Bateson, O.V. 1942. The role of the vertebral veins in metastatic process. Ann. Int. Med. 16: 38-45.
17. 17. McNEAL, J.E. 1993. Prostatic carcinomas in relation to cancer origin and evaluation to clinical cancer. Cancer 71: 984-991.
18. 18. Shevrin, D.H., K.I. Gorny & S.C. Kukreja. 1989. Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice. Prostate 15: 187-94.
19. 19. Geldof, A. & B.R. Rao. 1990. Prostatic tumor (R3327) skeletal metastasis. Prostate 16: 279-290.
20. 20. Paget, S. 1989. The distribution of secondary growth in cancer of the breast. (reprinted) Cancer Metast. Rev. 1: 571-573.
21. 21. Rembrink, K., J.C. Romun, T.H. Van Der Kwast et al. 1997. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 31(3): 168-174.
22. 22. Gleave, M.E., J.T. Hsieh, A.C. Von Eschenbach & L.W.K. Chung. 1992. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: Implications for bidirectional stromal-epithelial interaction in prostate carcinoma growth and metastasis. J. Urol. 147: 1151-1159.
23. 23. Gleave, M., J.T. Hsieh, C. Gao et al. 1991. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 51: 3753-3761.
24. 24. Hoosein, N.M., D.D. Boyd, W.J. Holas et al. 1991. Correlation of levels of urokinase and its receptor with the invasiveness of human prostatic carcinoma cell lines. Cancer Commun. 3: 255-264.
25. 25. Mignanti, P. & D.B. Rifkin. 1993. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73: 161-195.
26. 26. Liotta, L.A. & W.G. Stettler-Stevenson. 1993. Principles of molecular cell biology of cancer: cancer metastasis. In Cancer: Principles and Practice of Oncology, 4th ed., V.T. De Vita, S, Hellman & S.A. Rosenberg, Eds.: 134-149. Lippincott. Philadelphia.
27. 27. Nunn, S.E., D.M. Peehl & P. Cohen. 1997. Acid-activated insulin-like growth factor binding protein protease activity of Cathepsin D in normal and malignant prostate epithelial cells and seminal plasma. J. Cell Physiol. 171: 196-204.
28. 28. Webber, M.M., A. Waghary, D. Bello & J.S. Rhim. 1996. Mini review: protease and invasion in human prostate epithelial cell lines: implications in prostate cancer prevention and intervention. Radiat. Oncol. Invest. 3: 358-362.
29. 29. Stearns, M.E. & M. Wang. 1993. Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 53: 878-883.
30. 30. Lokeshwar, B.L., M.G. Selzer, N.L. Block & Z. Gunja-Smith. 1993. Secretion of matrix metalloproteinase and their inhibitors (TIMPs) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res. 53: 4493-4498.
31. 31. Festuccia, C., M. Bologna, C. Vincentini et al. 1996. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int. J. Cancer. 69: 386-393.
32. 32. Stearns M. & M.E. Stearns. 1996. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol. Res. 8: 69-75.
33. 33. Gleason, D.F. Classification of prostate carcinoma. 1966. Cancer Chemother. Rep. 50: 125-131.
34. 34. Wood M., K. Fudge, J.L. Mohler et al. 1997. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin. Exp. Metastasis. 15: 246-258.
35. 35. Powell, W.C., J.D. Knox, M. Navre et al. 1993. Expression of the metalloproteinase matrilysin in DU-145 cells increase their invasive potential in severe combined immunodeficient mice. Cancer Res. 53: 417-422.
36. 36. Stephenson, R.A., C.P.N. Dinney, K. Gohji et al. 1992. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst. 84: 951-957.
37. 37. Powell, W.C., F.E. Domann, Jr., J.M. Mitchen et al. 1996. Matrilysin expression in the involuting rat ventral prostate. Prostate 29: 159-168.
38. 38. Liotta L.A., P.S. Steeg & W.G. Stettler-Stevenson. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336.
39. 39. Stearns, M.E., K. Fudge, F. Garcia & M. Wang. 1997. IL-10 inhibition of human prostate PC-3ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metast. 17: 62-74.
40. 40. Jung, K., L. Nowak, M. Lien et al. 1997. Matrix metalloproteinases 1 and 3 tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase/tissue inhibitor in plasma of patients with prostate cancer. Int. J. Cancer. 74: 220-223.
41. 41. DeClerck, Y.A., N. Perez, H. Shimada et al. 1992. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinase. Canc. Res. 52: 701-708
42. 42. Khokha, R., M.J. Zimmer, C.H. Graham et al. 1992, Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-I (TIMP-1) in B16-F10 melanoma cells. J. Natl. Cancer Inst. 84: 1017-1022.
43. 43. DeClerck, Y.A., S, Imren, A.M. Montgomery et al. 1997. Proteases and proteases inhibitors in tumor progression. Adv. Exp. Med. Biol. 425: 89-97.
44. 44. Bodden, M.K, L.J. Windsor, N.C.M, Caterina et al. 1994. Analysis of timp-1/fib-cl complex. Ann. N.Y. Acad. Sci. 732: 84-95.
45. 45. Brown, P. 1994. Clinical trials of a low molecular weight matrix metalloproteinase inhibitor in cancer. Ann. NY Acad. Sci. 732: 217-221.
46. th NCI-EORTC Symposium on New Drug Development, Amsterdam, March 1994.
47. 47. Davies, B., P.D. Brown, N. East et al. 1993. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Canc. Res. 53: 2087-2091.
48. 48. Sledge, G.W., Jr., M. Qulali, R. Goulet et al. 1995. Effect of matrix metalloprotienase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst. 87: 1546-1550.
49. 49. Millar A. & P. Brown. 1996. 360 patient meta-analysis of studies of marimastat: a novel matrix metalloproteinase inhibitor. Ann. Oncol. 7(suppl. 5): 123.
50. 50. Poole, C., M. Adams, V. Barley et al. 1996. A dose finding study of marimastat, an oral matrix metalloprotienase inhibitor, in patients with advanced ovarian cancer. Ann. Oncol. 7(suppl. 5): 68.
51. 51. Stearns, M.E. & M. Wang. 1992. Taxol block processes essential for prostate tumor cell (PC-3ML) invasion and metastases. Cancer Res. 52: 3776-3781.
52. 52. Stearns, M.E. & M. Wang. 1996. Effects of alendronate and taxol on PCML cell bone metastases in SCID mice. Invasion Metast. 16: 116-131.
53. 53. Woitowicz-Praga, S.M., R.B. Dickson & M.J. Hawkins. 1997. Matrix metalloproteinase inhibitors. Invest. New Drugs 14: 62-75.
54. 54. Rasmussen, H.K. & P.P. McCann. 1997. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther. 75: 69-75.
55. 55. Golub, L.M., N.S. Ramamurthy & T.F. McNamara. 1991. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral. Biol. Med. 2: 297-322.
56. 56. Sipos, E.P., R.J. Tamargo, J.D. Weingert et al. 1994. Inhibition of tumor angiogensis. Ann. N.Y. Acad. Sci. 732: 263-272.
57. 57. Kroon, A.M., B.H.J. Dontie, M. Holtrop et al 1984. The mitochondrial genetic system as a target for chemotherapy; Tetracycline as cytostatics. Canc. Lett. 25; 33-80.
58. 58. Golub, L.M., K. Soummalainen & T. Sorsa. 1992. Host modulation with tetracyclines and their chemically modified analogues. Curr. Opi. Dent. 2: 80-90.
59. 59. Golub, L.M., N.S. Ramamurthy, T.F. McNamara et al. 1991. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral Biol. Med. 2: 297-322.
60. 60. Lokeshwar, B.L., M.G. Selzer, H.L. Houston-Clark et al. 1998. Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer. Adv. Dental Res. 12: 97-102.
61. 61. Yu, Z.M., K. Leung, N.S. Ramamurthy et al. 1992. HPLC determination of a chemically modified tetracycline: biological implications. Biochem. Med. Metab. Biol. 47: 10-20.
62. 62. Albini, A., Y. Iwamoto, H.K. Kleinman et al. A rapid in vitro assay for qauntitating the invasive potential of tumor cells. 1987. Cane. Res. 47: 3239-3245.
63. 63. Lokeshwar, B.L., M.G. Selzer, B-Q. Zhu et al. Inhibition of tumor growth and metastasis by oral administration of a non-antimicrobial tetracycline analogue (CMT-3), and doxycycline in a metastatic prostate cancer model. Clin. Cancer Res. Submitted for publication.
64. 64. Van Den Bogert, C., B.H.J. Dontei, M. Holtrop et al. 1986. Arrest of the proliferation of renal and prostate carcinomas of human origin by inhibition of mitochondrial protein synthesis. Cancer Res. 46: 3283-3289.
65. 65. Fife, R.S., G.W. Sledge, Jr., B.J. Roth & C. Proctor. 1998. Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett. 127: 37-41.
66. 66. Zucker, S., R.M. Lysik, N.S. Ramamurthy et al. 1985. Diversity of melanoma plasma membrane proteinases: Inhibition of collagenolytic and cytolytic activities by minocycline. J. Natl. Cancer Inst. 75: 517-525.
67. 67. Lokeshwar, B.A., S.M. Ferrell & N.L. Block. 1995. Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late-stage malignancy. Anticancer Res. 15: 93-98.
68. 68. Isaacs J.T., W.B. Isaacs, W.F. Feitz & J. Scheres. 1986. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281.
69. 69. Jacobs, S.C. 1983. Spread of prostate cancer to bone. Urology 21: 331-344.
70. 70. Sande, M.A. & G.L. Mandel. 1990. Antimicrobial agents: tetracycline, chloramphenicaol, erythromicin and miscellaneous antibacterial agents. In Goodman and Gilman's The Pharmacological Basis of Therapeutics. A.G. Oilman, T.W. Rall, A.S. Nies et al. Eds.: 117-125. Macmillan Publishing Co. New York.
71. 71. Sefter, R.E.B., E.A. Sefter, J.E. Delarco et al. 1998. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin. Exp. Metastasis. 16: 217-225.